P10636 |
TAU_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10636 |
TAU_HUMAN |
Alzheimer disease [ICD-11: 8A20] |
P10636 |
TAU_HUMAN |
Mild neurocognitive disorder [ICD-11: 6D71] |
P10636 |
TAU_HUMAN |
Choreiform disorder [ICD-11: 8A01] |
P10636 |
TAU_HUMAN |
Parkinsonism [ICD-11: 8A00] |
P10636 |
TAU_HUMAN |
Central nervous system disease [ICD-11: 8A04-8D87] |
P10636 |
TAU_HUMAN |
Neurodegenerative disorder [ICD-11: 8A20-8A23] |
P11473 |
VDR_HUMAN |
Chronic kidney disease [ICD-11: GB61] |
P11473 |
VDR_HUMAN |
Hair/hair growth developmental defect [ICD-11: LC30] |
P11473 |
VDR_HUMAN |
Hyper-parathyroidism [ICD-11: 5A51] |
P11473 |
VDR_HUMAN |
Hypo-parathyroidism [ICD-11: 5A50] |
P11473 |
VDR_HUMAN |
Mineral deficiency [ICD-11: 5B5K] |
P11473 |
VDR_HUMAN |
Psoriasis [ICD-11: EA90] |
P11473 |
VDR_HUMAN |
Vitamin deficiency [ICD-11: 5B55-5B5F] |
P11473 |
VDR_HUMAN |
Low bone mass disorder [ICD-11: FB83] |
P11473 |
VDR_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P11473 |
VDR_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P11473 |
VDR_HUMAN |
Prostate disease [ICD-11: GA91] |
P11473 |
VDR_HUMAN |
Abnormal micturition [ICD-11: MF50] |
P11473 |
VDR_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P11473 |
VDR_HUMAN |
Postoperative inflammation [ICD-11: 1A00-CA43] |
P11473 |
VDR_HUMAN |
Acne vulgaris [ICD-11: ED80] |
Q16637 |
SMN_HUMAN |
Muscular atrophy [ICD-11: 8B61] |
Q16637 |
SMN_HUMAN |
Muscular atrophy [ICD-11: 8B61] |
Q16637 |
SMN_HUMAN |
Muscular atrophy [ICD-11: 8B61] |
Q16637 |
SMN_HUMAN |
Muscular atrophy [ICD-11: 8B61] |
P08684 |
CP3A4_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P08684 |
CP3A4_HUMAN |
Atopic eczema [ICD-11: EA80] |
P08684 |
CP3A4_HUMAN |
Anxiety disorder [ICD-11: 6B00-6B0Z] |
P10275 |
ANDR_HUMAN |
Acne vulgaris [ICD-11: ED80] |
P10275 |
ANDR_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10275 |
ANDR_HUMAN |
Alcoholic liver disease [ICD-11: DB94] |
P10275 |
ANDR_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P10275 |
ANDR_HUMAN |
Cardiovascular disease [ICD-11: BA00-BE2Z] |
P10275 |
ANDR_HUMAN |
Chronic obstructive pulmonary disease [ICD-11: CA22] |
P10275 |
ANDR_HUMAN |
Female pelvic pain [ICD-11: GA34] |
P10275 |
ANDR_HUMAN |
Hypo-osmolality/hyponatraemia [ICD-11: 5C72] |
P10275 |
ANDR_HUMAN |
Low bone mass disorder [ICD-11: FB83] |
P10275 |
ANDR_HUMAN |
Mammary tumour [ICD-11: 2C60-2C6Z] |
P10275 |
ANDR_HUMAN |
Pituitary gland disorder [ICD-11: 5A60-5A61] |
P10275 |
ANDR_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P10275 |
ANDR_HUMAN |
Testicular dysfunction [ICD-11: 5A81] |
P10275 |
ANDR_HUMAN |
Prostate hyperplasia [ICD-11: GA90] |
P10275 |
ANDR_HUMAN |
Alopecia [ICD-11: ED70] |
P10275 |
ANDR_HUMAN |
Chronic kidney disease [ICD-11: GB61] |
P10275 |
ANDR_HUMAN |
Thrombosis [ICD-11: DB61-GB90] |
P10275 |
ANDR_HUMAN |
Contraceptive management [ICD-11: QA21] |
P10275 |
ANDR_HUMAN |
Heart failure [ICD-11: BD10-BD1Z] |
P10275 |
ANDR_HUMAN |
Muscle disorder [ICD-11: FB32-FB3Z] |
P10275 |
ANDR_HUMAN |
Muscular dystrophy [ICD-11: 8C70] |
P10275 |
ANDR_HUMAN |
Cystic fibrosis [ICD-11: CA25] |
P10275 |
ANDR_HUMAN |
Pain [ICD-11: MG30-MG3Z] |
P10275 |
ANDR_HUMAN |
Cachexia [ICD-11: MG20] |
P10275 |
ANDR_HUMAN |
Dissociative neurological symptom disorder [ICD-11: 6B60] |
P10275 |
ANDR_HUMAN |
Bladder cancer [ICD-11: 2C94] |
P10275 |
ANDR_HUMAN |
Oesophagitis [ICD-11: DA24] |
P10275 |
ANDR_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10275 |
ANDR_HUMAN |
Prostate hyperplasia [ICD-11: GA90] |
P10275 |
ANDR_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P10275 |
ANDR_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P10275 |
ANDR_HUMAN |
Acne vulgaris [ICD-11: ED80] |
P10275 |
ANDR_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P84022 |
SMAD3_HUMAN |
Herpes simplex infection [ICD-11: 1F00] |
P84022 |
SMAD3_HUMAN |
Kidney fibrosis [ICD-11: GC01] |
Q16236 |
NF2L2_HUMAN |
Ataxic disorder [ICD-11: 8A03] |
Q16236 |
NF2L2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
Q16236 |
NF2L2_HUMAN |
Glaucoma [ICD-11: 9C61] |
Q16236 |
NF2L2_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q16236 |
NF2L2_HUMAN |
Macular degeneration [ICD-11: 9B75] |
Q16236 |
NF2L2_HUMAN |
Melanoma [ICD-11: 2C30] |
Q16236 |
NF2L2_HUMAN |
Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] |
Q16236 |
NF2L2_HUMAN |
Pulmonary hypertension [ICD-11: BB01] |
Q16236 |
NF2L2_HUMAN |
Subarachnoid haemorrhage [ICD-11: 8B01] |
Q16236 |
NF2L2_HUMAN |
Urinary system clinical sympton [ICD-11: MF8Y] |
Q16236 |
NF2L2_HUMAN |
Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q16236 |
NF2L2_HUMAN |
Alpha-1-antitrypsin deficiency [ICD-11: 5C5A] |
Q16236 |
NF2L2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
Q16236 |
NF2L2_HUMAN |
Multiple sclerosis [ICD-11: 8A40] |
P19838 |
NFKB1_HUMAN |
Muscular dystrophy [ICD-11: 8C70] |
P19838 |
NFKB1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P19838 |
NFKB1_HUMAN |
Type 2 diabetes mellitus [ICD-11: 5A11] |
P27695 |
APEX1_HUMAN |
Retinopathy [ICD-11: 9B71] |
P27695 |
APEX1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P27695 |
APEX1_HUMAN |
Ocular cancer [ICD-11: 2D00-2D07] |
P27695 |
APEX1_HUMAN |
Brain cancer [ICD-11: 2A00] |
P27695 |
APEX1_HUMAN |
Melanoma [ICD-11: 2C30] |
P37840 |
SYUA_HUMAN |
Parkinsonism [ICD-11: 8A00] |
P37840 |
SYUA_HUMAN |
Alzheimer disease [ICD-11: 8A20] |
P37840 |
SYUA_HUMAN |
Autonomic nervous system disorder [ICD-11: 8D87] |
O94782 |
UBP1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q13526 |
PIN1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q13526 |
PIN1_HUMAN |
Nasopharyngeal cancer [ICD-11: 2B6B] |
P03372 |
ESR1_HUMAN |
Acne vulgaris [ICD-11: ED80] |
P03372 |
ESR1_HUMAN |
Acquired prion disease [ICD-11: 8E01] |
P03372 |
ESR1_HUMAN |
Adrenal cancer [ICD-11: 2D11] |
P03372 |
ESR1_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P03372 |
ESR1_HUMAN |
Contraceptive management [ICD-11: QA21] |
P03372 |
ESR1_HUMAN |
Dyspareunia [ICD-11: GA12] |
P03372 |
ESR1_HUMAN |
Female infertility [ICD-11: GA31] |
P03372 |
ESR1_HUMAN |
Low bone mass disorder [ICD-11: FB83] |
P03372 |
ESR1_HUMAN |
Male infertility [ICD-11: GB04] |
P03372 |
ESR1_HUMAN |
Menopausal disorder [ICD-11: GA30] |
P03372 |
ESR1_HUMAN |
Menstrual cycle bleeding disorder [ICD-11: GA20] |
P03372 |
ESR1_HUMAN |
Multiple sclerosis [ICD-11: 8A40] |
P03372 |
ESR1_HUMAN |
Pituitary gland disorder [ICD-11: 5A60-5A61] |
P03372 |
ESR1_HUMAN |
Skeletal anomaly [ICD-11: LD24] |
P03372 |
ESR1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P03372 |
ESR1_HUMAN |
Vaginitis [ICD-11: GA02] |
P03372 |
ESR1_HUMAN |
Virus infection [ICD-11: 1A24-1D9Z] |
P03372 |
ESR1_HUMAN |
Endometriosis [ICD-11: GA10] |
P03372 |
ESR1_HUMAN |
Female genital tract noninflammatory disorder [ICD-11: GA1Y] |
P03372 |
ESR1_HUMAN |
Female pelvic pain [ICD-11: GA34] |
P03372 |
ESR1_HUMAN |
Hyper-lipoproteinaemia [ICD-11: 5C80] |
P03372 |
ESR1_HUMAN |
Breast in situ carcinoma [ICD-11: 2E65] |
P03372 |
ESR1_HUMAN |
Diabetes mellitus [ICD-11: 5A10] |
P03372 |
ESR1_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P03372 |
ESR1_HUMAN |
Brain cancer [ICD-11: 2A00] |
P03372 |
ESR1_HUMAN |
Metastatic tumour [ICD-11: 2D50-2E2Z] |
P03372 |
ESR1_HUMAN |
Irregularities [ICD-11: N.A.] |
P03372 |
ESR1_HUMAN |
Trematode disease [ICD-11: 1F8Y] |
P03372 |
ESR1_HUMAN |
Pain [ICD-11: MG30-MG3Z] |
P03372 |
ESR1_HUMAN |
Eye disorder [ICD-11: 9A01-9A0Z] |
P03372 |
ESR1_HUMAN |
Dissociative neurological symptom disorder [ICD-11: 6B60] |
P03372 |
ESR1_HUMAN |
Thrombocytopenia [ICD-11: 3B64] |
P03372 |
ESR1_HUMAN |
Atrophy [ICD-11: 9A2Y-9C40] |
P03372 |
ESR1_HUMAN |
Joint pain [ICD-11: ME82] |
P03372 |
ESR1_HUMAN |
Sexual dysfunction [ICD-11: HA00-HA01] |
P03372 |
ESR1_HUMAN |
Leukaemia [ICD-11: 2A60-2B33] |
P04150 |
GCR_HUMAN |
Acute diabete complication [ICD-11: 5A2Y] |
P04150 |
GCR_HUMAN |
Indeterminate colitis [ICD-11: DD72] |
P04150 |
GCR_HUMAN |
Multiple sclerosis [ICD-11: 8A40] |
P04150 |
GCR_HUMAN |
Muscular dystrophy [ICD-11: 8C70] |
P04150 |
GCR_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P04150 |
GCR_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
P04150 |
GCR_HUMAN |
Type 2 diabetes mellitus [ICD-11: 5A11] |
P04150 |
GCR_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P04150 |
GCR_HUMAN |
Adaptive immunity immunodeficiency [ICD-11: 4A01] |
P04150 |
GCR_HUMAN |
Adrenogenital disorder [ICD-11: 5A71] |
P04150 |
GCR_HUMAN |
Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] |
P04150 |
GCR_HUMAN |
Asthma [ICD-11: CA23] |
P04150 |
GCR_HUMAN |
Atopic eczema [ICD-11: EA80] |
P04150 |
GCR_HUMAN |
Chronic obstructive pulmonary disease [ICD-11: CA22] |
P04150 |
GCR_HUMAN |
Cushing syndrome [ICD-11: 5A70] |
P04150 |
GCR_HUMAN |
Eczema [ICD-11: EA80-EA89] |
P04150 |
GCR_HUMAN |
Multiple sclerosis [ICD-11: 8A40] |
P04150 |
GCR_HUMAN |
Muscular dystrophy [ICD-11: 8C70] |
P04150 |
GCR_HUMAN |
Oesophagitis [ICD-11: DA24] |
P04150 |
GCR_HUMAN |
Postoperative inflammation [ICD-11: 1A00-CA43] |
P04150 |
GCR_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
P04150 |
GCR_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P04150 |
GCR_HUMAN |
Spine/trunk injury [ICD-11: ND51] |
P04150 |
GCR_HUMAN |
Vasomotor/allergic rhinitis [ICD-11: CA08] |
P04150 |
GCR_HUMAN |
Herpes simplex infection [ICD-11: 1F00] |
P04150 |
GCR_HUMAN |
Otitis externa [ICD-11: AA00-AA13] |
P04150 |
GCR_HUMAN |
Substance abuse [ICD-11: 6C40] |
P04150 |
GCR_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P04150 |
GCR_HUMAN |
Depression [ICD-11: 6A70-6A7Z] |
P04150 |
GCR_HUMAN |
Mood disorder [ICD-11: 6A60-6E23] |
P04150 |
GCR_HUMAN |
Type 2 diabetes mellitus [ICD-11: 5A11] |
P04150 |
GCR_HUMAN |
Vitamin deficiency [ICD-11: 5B55-5B5F] |
P04150 |
GCR_HUMAN |
Retinopathy [ICD-11: 9B71] |
P04150 |
GCR_HUMAN |
Anxiety disorder [ICD-11: 6B00-6B0Z] |
P10635 |
CP2D6_HUMAN |
Insomnia [ICD-11: 7A00-7A0Z] |
P10635 |
CP2D6_HUMAN |
Malaria [ICD-11: 1F40-1F45] |
P10635 |
CP2D6_HUMAN |
Migraine [ICD-11: 8A80] |
P11712 |
CP2C9_HUMAN |
Bacterial infection [ICD-11: 1A00-1C4Z] |
P21728 |
DRD1_HUMAN |
Abortion [ICD-11: JA00] |
P21728 |
DRD1_HUMAN |
Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] |
P21728 |
DRD1_HUMAN |
Hypertension [ICD-11: BA00-BA04] |
P21728 |
DRD1_HUMAN |
Parkinsonism [ICD-11: 8A00] |
P21728 |
DRD1_HUMAN |
Cocaine use disorder [ICD-11: 6C45] |
P21728 |
DRD1_HUMAN |
Schizophrenia [ICD-11: 6A20] |
P21728 |
DRD1_HUMAN |
Tic disorder [ICD-11: 8A05] |
P21728 |
DRD1_HUMAN |
Dementia [ICD-11: 6D80-6D8Z] |
P21728 |
DRD1_HUMAN |
Psychotic disorder [ICD-11: 6A20-6A25] |
P21728 |
DRD1_HUMAN |
Mild neurocognitive disorder [ICD-11: 6D71] |
P21728 |
DRD1_HUMAN |
Pain [ICD-11: MG30-MG3Z] |
P21728 |
DRD1_HUMAN |
Glaucoma [ICD-11: 9C61] |
P21728 |
DRD1_HUMAN |
Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] |
P21728 |
DRD1_HUMAN |
Type 2 diabetes mellitus [ICD-11: 5A11] |
P21728 |
DRD1_HUMAN |
Unspecific substance use disorder [ICD-11: 6C4Z] |
P28482 |
MK01_HUMAN |
Melanoma [ICD-11: 2C30] |
P28482 |
MK01_HUMAN |
Pancreatic cancer [ICD-11: 2C10] |
P28482 |
MK01_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P28482 |
MK01_HUMAN |
Arteries/arterioles disorder [ICD-11: BD52] |
P28482 |
MK01_HUMAN |
Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] |
P28482 |
MK01_HUMAN |
Transplant rejection [ICD-11: NE84] |
P28482 |
MK01_HUMAN |
Mature T-cell lymphoma [ICD-11: 2A90] |
P28482 |
MK01_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
P29466 |
CASP1_HUMAN |
Epilepsy/seizure [ICD-11: 8A61-8A6Z] |
P29466 |
CASP1_HUMAN |
Fibrosis [ICD-11: GA14-GC01] |
P29466 |
CASP1_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
P29466 |
CASP1_HUMAN |
Type 2 diabetes mellitus [ICD-11: 5A11] |
P29466 |
CASP1_HUMAN |
Contact dermatitis [ICD-11: EK00-EK0Z] |
P29466 |
CASP1_HUMAN |
Fragrance/cosmetics phototoxic reaction [ICD-11: EK20] |
P29466 |
CASP1_HUMAN |
Irritant contact dermatitis [ICD-11: EK02] |
P29466 |
CASP1_HUMAN |
Epilepsy/seizure [ICD-11: 8A61-8A6Z] |
P29466 |
CASP1_HUMAN |
Fibrosis [ICD-11: GA14-GC01] |
P29466 |
CASP1_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
P29466 |
CASP1_HUMAN |
Type 2 diabetes mellitus [ICD-11: 5A11] |
P29466 |
CASP1_HUMAN |
Contact dermatitis [ICD-11: EK00-EK0Z] |
P29466 |
CASP1_HUMAN |
Fragrance/cosmetics phototoxic reaction [ICD-11: EK20] |
P29466 |
CASP1_HUMAN |
Irritant contact dermatitis [ICD-11: EK02] |
Q92731 |
ESR2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
Q92731 |
ESR2_HUMAN |
Cushing syndrome [ICD-11: 5A70] |
Q92731 |
ESR2_HUMAN |
Menopausal disorder [ICD-11: GA30] |
Q92731 |
ESR2_HUMAN |
Vasomotor/allergic rhinitis [ICD-11: CA08] |
Q92731 |
ESR2_HUMAN |
Hepatitis virus infection [ICD-11: 1E50-1E51] |
Q92731 |
ESR2_HUMAN |
Hyper-lipoproteinaemia [ICD-11: 5C80] |
Q92731 |
ESR2_HUMAN |
Prostate cancer [ICD-11: 2C82] |
Q92731 |
ESR2_HUMAN |
Alzheimer disease [ICD-11: 8A20] |
Q92731 |
ESR2_HUMAN |
Indeterminate colitis [ICD-11: DD72] |
Q92731 |
ESR2_HUMAN |
Prostate hyperplasia [ICD-11: GA90] |
Q92731 |
ESR2_HUMAN |
Sepsis [ICD-11: 1G40-1G41] |
Q92731 |
ESR2_HUMAN |
Irregularities [ICD-11: N.A.] |
Q92731 |
ESR2_HUMAN |
Trematode disease [ICD-11: 1F8Y] |
Q92731 |
ESR2_HUMAN |
Low bone mass disorder [ICD-11: FB83] |
Q92731 |
ESR2_HUMAN |
Thrombocytopenia [ICD-11: 3B64] |
Q92731 |
ESR2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q92731 |
ESR2_HUMAN |
Herpes simplex infection [ICD-11: 1F00] |
Q92731 |
ESR2_HUMAN |
Postoperative inflammation [ICD-11: 1A00-CA43] |
Q96KQ7 |
EHMT2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
Q96KQ7 |
EHMT2_HUMAN |
Postoperative inflammation [ICD-11: 1A00-CA43] |
Q96KQ7 |
EHMT2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P25779 |
CYSP_TRYCR |
Parasitic worm infestation [ICD-11: 1F90] |
P25779 |
CYSP_TRYCR |
Malaria [ICD-11: 1F40-1F45] |
P55210 |
CASP7_HUMAN |
Cystic fibrosis [ICD-11: CA25] |
P06746 |
DPOLB_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10828 |
THB_HUMAN |
Hyper-lipoproteinaemia [ICD-11: 5C80] |
P10828 |
THB_HUMAN |
Hypo-thyroidism [ICD-11: 5A00] |
P10828 |
THB_HUMAN |
Inborn lipid metabolism error [ICD-11: 5C52] |
P10828 |
THB_HUMAN |
Skin postprocedural disorder [ICD-11: EL8Y] |
P10828 |
THB_HUMAN |
Thyrotoxicosis [ICD-11: 5A02] |
Q16665 |
HIF1A_HUMAN |
Adrenomedullary hyperfunction [ICD-11: 5A75] |
Q16665 |
HIF1A_HUMAN |
Brain cancer [ICD-11: 2A00] |
Q16665 |
HIF1A_HUMAN |
Lymphoma [ICD-11: 2A80-2A86] |
Q16665 |
HIF1A_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q16665 |
HIF1A_HUMAN |
Pulmonary hypertension [ICD-11: BB01] |
P37231 |
PPARG_HUMAN |
Pulmonary hypertension [ICD-11: BB01] |
P37231 |
PPARG_HUMAN |
Sjogren syndrome [ICD-11: 4A43] |
P37231 |
PPARG_HUMAN |
Type 2 diabetes mellitus [ICD-11: 5A11] |
P37231 |
PPARG_HUMAN |
Acute diabete complication [ICD-11: 5A2Y] |
P37231 |
PPARG_HUMAN |
Alzheimer disease [ICD-11: 8A20] |
P37231 |
PPARG_HUMAN |
Obesity [ICD-11: 5B80-5B81] |
P37231 |
PPARG_HUMAN |
Type 2 diabetes mellitus [ICD-11: 5A11] |
P37231 |
PPARG_HUMAN |
Diabetes mellitus [ICD-11: 5A10] |
P37231 |
PPARG_HUMAN |
Glaucoma [ICD-11: 9C61] |
P37231 |
PPARG_HUMAN |
Inborn lipid metabolism error [ICD-11: 5C52] |
P37231 |
PPARG_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P37231 |
PPARG_HUMAN |
Gout [ICD-11: FA25] |
P37231 |
PPARG_HUMAN |
Indeterminate colitis [ICD-11: DD72] |
P37231 |
PPARG_HUMAN |
Multiple sclerosis [ICD-11: 8A40] |
P37231 |
PPARG_HUMAN |
Nicotine use disorder [ICD-11: 6C4A] |
P37231 |
PPARG_HUMAN |
Non-alcoholic fatty liver disease [ICD-11: DB92] |
P37231 |
PPARG_HUMAN |
Opioid use disorder [ICD-11: 6C43] |
P37231 |
PPARG_HUMAN |
Hyper-lipoproteinaemia [ICD-11: 5C80] |
P37231 |
PPARG_HUMAN |
Idiopathic interstitial pneumonitis [ICD-11: CB03] |
P37231 |
PPARG_HUMAN |
Metabolic disorder [ICD-11: 5C50-5D2Z] |
P10809 |
CH60_HUMAN |
Diabetes mellitus [ICD-11: 5A10] |
P10809 |
CH60_HUMAN |
Diabetes mellitus [ICD-11: 5A10] |
P55072 |
TERA_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P55072 |
TERA_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P55072 |
TERA_HUMAN |
Myelodysplastic syndrome [ICD-11: 2A37] |
P55072 |
TERA_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P11021 |
BIP_HUMAN |
Melanoma [ICD-11: 2C30] |
P11021 |
BIP_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q03181 |
PPARD_HUMAN |
Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q03181 |
PPARD_HUMAN |
Type 2 diabetes mellitus [ICD-11: 5A11] |
Q03181 |
PPARD_HUMAN |
Autoimmune liver disease [ICD-11: DB96] |
Q03181 |
PPARD_HUMAN |
Hyper-lipoproteinaemia [ICD-11: 5C80] |
Q03181 |
PPARD_HUMAN |
Obesity [ICD-11: 5B80-5B81] |
Q03181 |
PPARD_HUMAN |
Alzheimer disease [ICD-11: 8A20] |
Q03181 |
PPARD_HUMAN |
Dyslipidemia [ICD-11: 5C80-5C81] |
Q03181 |
PPARD_HUMAN |
Metabolic disorder [ICD-11: 5C50-5D2Z] |
Q03181 |
PPARD_HUMAN |
Diabetes mellitus [ICD-11: 5A10] |
Q03181 |
PPARD_HUMAN |
Central nervous system disease [ICD-11: 8A04-8D87] |
P15917 |
LEF_BACAN |
Sepsis [ICD-11: 1G40-1G41] |
P15917 |
LEF_BACAN |
Corneal disease [ICD-11: 9A76-9A78] |
Q07817 |
B2CL1_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
Q07817 |
B2CL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07817 |
B2CL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07817 |
B2CL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07817 |
B2CL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07817 |
B2CL1_HUMAN |
Mature T-cell lymphoma [ICD-11: 2A90] |
Q07817 |
B2CL1_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
Q07817 |
B2CL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07817 |
B2CL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07817 |
B2CL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07817 |
B2CL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07817 |
B2CL1_HUMAN |
Mature T-cell lymphoma [ICD-11: 2A90] |
Q07817 |
B2CL1_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
Q07817 |
B2CL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07817 |
B2CL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07817 |
B2CL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07817 |
B2CL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07817 |
B2CL1_HUMAN |
Mature T-cell lymphoma [ICD-11: 2A90] |
Q07817 |
B2CL1_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
Q07817 |
B2CL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07817 |
B2CL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07817 |
B2CL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07817 |
B2CL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07817 |
B2CL1_HUMAN |
Mature T-cell lymphoma [ICD-11: 2A90] |
Q07817 |
B2CL1_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
Q07817 |
B2CL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07817 |
B2CL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07817 |
B2CL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07817 |
B2CL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07817 |
B2CL1_HUMAN |
Mature T-cell lymphoma [ICD-11: 2A90] |
Q07817 |
B2CL1_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
Q07817 |
B2CL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07817 |
B2CL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07817 |
B2CL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07817 |
B2CL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07817 |
B2CL1_HUMAN |
Mature T-cell lymphoma [ICD-11: 2A90] |
Q07817 |
B2CL1_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
Q07817 |
B2CL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07817 |
B2CL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07817 |
B2CL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07817 |
B2CL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07817 |
B2CL1_HUMAN |
Mature T-cell lymphoma [ICD-11: 2A90] |
Q07817 |
B2CL1_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
Q07817 |
B2CL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07817 |
B2CL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07817 |
B2CL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07817 |
B2CL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07817 |
B2CL1_HUMAN |
Mature T-cell lymphoma [ICD-11: 2A90] |
Q07817 |
B2CL1_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
Q07817 |
B2CL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07817 |
B2CL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07817 |
B2CL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07817 |
B2CL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07817 |
B2CL1_HUMAN |
Mature T-cell lymphoma [ICD-11: 2A90] |
Q07817 |
B2CL1_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
Q07817 |
B2CL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07817 |
B2CL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07817 |
B2CL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07817 |
B2CL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07817 |
B2CL1_HUMAN |
Mature T-cell lymphoma [ICD-11: 2A90] |
Q07817 |
B2CL1_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
Q07817 |
B2CL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07817 |
B2CL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07817 |
B2CL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07817 |
B2CL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07817 |
B2CL1_HUMAN |
Mature T-cell lymphoma [ICD-11: 2A90] |
Q07817 |
B2CL1_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
Q07817 |
B2CL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07817 |
B2CL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07817 |
B2CL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07817 |
B2CL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07817 |
B2CL1_HUMAN |
Mature T-cell lymphoma [ICD-11: 2A90] |
Q07817 |
B2CL1_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
Q07817 |
B2CL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07817 |
B2CL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07817 |
B2CL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07817 |
B2CL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07817 |
B2CL1_HUMAN |
Mature T-cell lymphoma [ICD-11: 2A90] |
P19793 |
RXRA_HUMAN |
Kaposi sarcoma [ICD-11: 2B57] |
P19793 |
RXRA_HUMAN |
Mycosis fungoides [ICD-11: 2B01] |
P42858 |
HD_HUMAN |
Choreiform disorder [ICD-11: 8A01] |
P51151 |
RAB9A_HUMAN |
Fungal infection [ICD-11: 1F29-1F2F] |
P42345 |
MTOR_HUMAN |
Arteries/arterioles disorder [ICD-11: BD52] |
P42345 |
MTOR_HUMAN |
Chronic myelomonocytic leukaemia [ICD-11: 2A40] |
P42345 |
MTOR_HUMAN |
Hydrocephalus [ICD-11: 8D64] |
P42345 |
MTOR_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P42345 |
MTOR_HUMAN |
Renal cell carcinoma [ICD-11: 2C90] |
P42345 |
MTOR_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P42345 |
MTOR_HUMAN |
Transplant rejection [ICD-11: NE84] |
P42345 |
MTOR_HUMAN |
Sarcoma [ICD-11: 2A60-2C35] |
P42345 |
MTOR_HUMAN |
Bladder cancer [ICD-11: 2C94] |
P42345 |
MTOR_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P42345 |
MTOR_HUMAN |
Endometrial cancer [ICD-11: 2C76] |
P42345 |
MTOR_HUMAN |
Head and neck cancer [ICD-11: 2D42] |
P42345 |
MTOR_HUMAN |
Liver cancer [ICD-11: 2C12] |
P42345 |
MTOR_HUMAN |
Lung cancer [ICD-11: 2C25] |
P42345 |
MTOR_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P42345 |
MTOR_HUMAN |
Malignant mesenchymal neoplasm [ICD-11: 2B5D-2B5Y] |
P42345 |
MTOR_HUMAN |
Metastatic lymph node neoplasm [ICD-11: 2D60] |
P42345 |
MTOR_HUMAN |
Pain [ICD-11: MG30-MG3Z] |
P42345 |
MTOR_HUMAN |
Pancreatic cancer [ICD-11: 2C10] |
P42345 |
MTOR_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P42345 |
MTOR_HUMAN |
Pulmonary hypertension [ICD-11: BB01] |
P42345 |
MTOR_HUMAN |
Lymphangioleiomyomatosis [ICD-11: CB07] |
P42345 |
MTOR_HUMAN |
Lymphoma [ICD-11: 2A80-2A86] |
P42345 |
MTOR_HUMAN |
Pleural mesothelioma [ICD-11: 2C26] |
P42345 |
MTOR_HUMAN |
Mature T-cell lymphoma [ICD-11: 2A90] |
P42345 |
MTOR_HUMAN |
Postoperative inflammation [ICD-11: 1A00-CA43] |
P42345 |
MTOR_HUMAN |
Ulcerative colitis [ICD-11: DD71] |
O75604 |
UBP2_HUMAN |
Postoperative inflammation [ICD-11: 1A00-CA43] |
P04637 |
P53_HUMAN |
Arterial occlusive disease [ICD-11: BD40] |
P04637 |
P53_HUMAN |
Lip/oral cavity/pharynx neoplasm [ICD-11: 2B6E] |
P04637 |
P53_HUMAN |
Metastatic liver/bile duct neoplasm [ICD-11: 2D80] |
P04637 |
P53_HUMAN |
Transplant rejection [ICD-11: NE84] |
P04637 |
P53_HUMAN |
Ovarian dysfunction [ICD-11: 5A80] |
P04637 |
P53_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P04637 |
P53_HUMAN |
Bladder cancer [ICD-11: 2C94] |
P04637 |
P53_HUMAN |
Brain cancer [ICD-11: 2A00] |
P04637 |
P53_HUMAN |
Colorectal cancer [ICD-11: 2B91] |
P04637 |
P53_HUMAN |
Esophageal cancer [ICD-11: 2B70] |
P04637 |
P53_HUMAN |
Head and neck cancer [ICD-11: 2D42] |
P04637 |
P53_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
P04637 |
P53_HUMAN |
Myelodysplastic syndrome [ICD-11: 2A37] |
P04637 |
P53_HUMAN |
Ovarian cancer [ICD-11: 2C73] |
P04637 |
P53_HUMAN |
Pancreatic cancer [ICD-11: 2C10] |
P04637 |
P53_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P04637 |
P53_HUMAN |
Stomach cancer [ICD-11: 2B72] |
P04637 |
P53_HUMAN |
Cervical cancer [ICD-11: 2C77] |
P04637 |
P53_HUMAN |
Endometrial cancer [ICD-11: 2C76] |
P04637 |
P53_HUMAN |
Fallopian tube cancer [ICD-11: 2C74] |
P04637 |
P53_HUMAN |
Liposarcoma [ICD-11: 2B59] |
P04637 |
P53_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P04637 |
P53_HUMAN |
Peritoneal cancer [ICD-11: 2C51] |
P04637 |
P53_HUMAN |
Toxicity [ICD-11: N.A.] |
P04637 |
P53_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P04637 |
P53_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P04637 |
P53_HUMAN |
Kidney failure [ICD-11: GB60-GB6Z] |
P04637 |
P53_HUMAN |
Hearing disorder [ICD-11: AB50-AB57] |
P15121 |
ALDR_HUMAN |
Neuropathy [ICD-11: 8C0Z] |
P15121 |
ALDR_HUMAN |
Pain [ICD-11: MG30-MG3Z] |
P15121 |
ALDR_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
P15121 |
ALDR_HUMAN |
Acute diabete complication [ICD-11: 5A2Y] |
P15121 |
ALDR_HUMAN |
Thrombosis [ICD-11: DB61-GB90] |
P15121 |
ALDR_HUMAN |
Cataract [ICD-11: 9B10] |
P15121 |
ALDR_HUMAN |
Glaucoma [ICD-11: 9C61] |
P15121 |
ALDR_HUMAN |
Schizophrenia [ICD-11: 6A20] |
P15121 |
ALDR_HUMAN |
Gout [ICD-11: FA25] |
P15121 |
ALDR_HUMAN |
Head and neck cancer [ICD-11: 2D42] |
Q96RI1 |
NR1H4_HUMAN |
Autoimmune liver disease [ICD-11: DB96] |
Q96RI1 |
NR1H4_HUMAN |
Cholelithiasis [ICD-11: DC11] |
Q96RI1 |
NR1H4_HUMAN |
Insomnia [ICD-11: 7A00-7A0Z] |
Q96RI1 |
NR1H4_HUMAN |
Osteoarthritis [ICD-11: FA00-FA05] |
Q96RI1 |
NR1H4_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
Q96RI1 |
NR1H4_HUMAN |
Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q96RI1 |
NR1H4_HUMAN |
Chronic kidney disease [ICD-11: GB61] |
Q96RI1 |
NR1H4_HUMAN |
Skeletal anomaly [ICD-11: LD24] |
Q96RI1 |
NR1H4_HUMAN |
Hepatic fibrosis/cirrhosis [ICD-11: DB93] |
Q96RI1 |
NR1H4_HUMAN |
Hyper-lipoproteinaemia [ICD-11: 5C80] |
Q96RI1 |
NR1H4_HUMAN |
Type 2 diabetes mellitus [ICD-11: 5A11] |
Q07869 |
PPARA_HUMAN |
Cardiovascular disease [ICD-11: BA00-BE2Z] |
Q07869 |
PPARA_HUMAN |
Hyperlipidemia [ICD-11: 5C80] |
Q07869 |
PPARA_HUMAN |
Hyper-lipoproteinaemia [ICD-11: 5C80] |
Q07869 |
PPARA_HUMAN |
Inborn lipid metabolism error [ICD-11: 5C52] |
Q07869 |
PPARA_HUMAN |
Type 2 diabetes mellitus [ICD-11: 5A11] |
Q07869 |
PPARA_HUMAN |
Diabetes mellitus [ICD-11: 5A10] |
Q07869 |
PPARA_HUMAN |
Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q07869 |
PPARA_HUMAN |
Acute diabete complication [ICD-11: 5A2Y] |
Q07869 |
PPARA_HUMAN |
Dyslipidemia [ICD-11: 5C80-5C81] |
Q07869 |
PPARA_HUMAN |
Gout [ICD-11: FA25] |
Q07869 |
PPARA_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07869 |
PPARA_HUMAN |
Heart failure [ICD-11: BD10-BD1Z] |
Q07869 |
PPARA_HUMAN |
Arterial occlusive disease [ICD-11: BD40] |
Q07869 |
PPARA_HUMAN |
Idiopathic interstitial pneumonitis [ICD-11: CB03] |
Q07869 |
PPARA_HUMAN |
Metabolic disorder [ICD-11: 5C50-5D2Z] |
Q07869 |
PPARA_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
P15289 |
ARSA_HUMAN |
Lysosomal disease [ICD-11: 5C56] |
Q00987 |
MDM2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
Q00987 |
MDM2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q00987 |
MDM2_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q00987 |
MDM2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q00987 |
MDM2_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
Q00987 |
MDM2_HUMAN |
Myelodysplastic syndrome [ICD-11: 2A37] |
Q00987 |
MDM2_HUMAN |
Neuroendocrine carcinoma [ICD-11: 2C34] |
Q00987 |
MDM2_HUMAN |
Liposarcoma [ICD-11: 2B59] |
Q00987 |
MDM2_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q00987 |
MDM2_HUMAN |
Prostate cancer [ICD-11: 2C82] |
Q00987 |
MDM2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
Q00987 |
MDM2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10253 |
LYAG_HUMAN |
Inborn carbohydrate metabolism error [ICD-11: 5C51] |
P02768 |
ALBU_HUMAN |
Aneurysm/dissection [ICD-11: BD50] |
P02768 |
ALBU_HUMAN |
Bowel habit change [ICD-11: ME05] |
P02768 |
ALBU_HUMAN |
Cholelithiasis [ICD-11: DC11] |
P02768 |
ALBU_HUMAN |
Inborn energy metabolism error [ICD-11: 5C53] |
P02768 |
ALBU_HUMAN |
Irritable bowel syndrome [ICD-11: DD91] |
P02768 |
ALBU_HUMAN |
Preprocedural examination [ICD-11: QA0B] |
P02768 |
ALBU_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
P02768 |
ALBU_HUMAN |
Schizophrenia [ICD-11: 6A20] |
P02768 |
ALBU_HUMAN |
Unspecific body region injury [ICD-11: ND56] |
P02768 |
ALBU_HUMAN |
Coagulation defect [ICD-11: 3B10] |
P02768 |
ALBU_HUMAN |
Lupus erythematosus [ICD-11: 4A40] |
P02768 |
ALBU_HUMAN |
Vitamin deficiency [ICD-11: 5B55-5B5F] |
P52732 |
KIF11_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P52732 |
KIF11_HUMAN |
Head and neck cancer [ICD-11: 2D42] |
P52732 |
KIF11_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P52732 |
KIF11_HUMAN |
Ovarian cancer [ICD-11: 2C73] |
P52732 |
KIF11_HUMAN |
Renal cell carcinoma [ICD-11: 2C90] |
P52732 |
KIF11_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P52732 |
KIF11_HUMAN |
Lymphoma [ICD-11: 2A80-2A86] |
P52732 |
KIF11_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P52732 |
KIF11_HUMAN |
Liver cancer [ICD-11: 2C12] |
P52732 |
KIF11_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P52732 |
KIF11_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P52732 |
KIF11_HUMAN |
Head and neck cancer [ICD-11: 2D42] |
P52732 |
KIF11_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P52732 |
KIF11_HUMAN |
Ovarian cancer [ICD-11: 2C73] |
P52732 |
KIF11_HUMAN |
Renal cell carcinoma [ICD-11: 2C90] |
P52732 |
KIF11_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P52732 |
KIF11_HUMAN |
Lymphoma [ICD-11: 2A80-2A86] |
P52732 |
KIF11_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P52732 |
KIF11_HUMAN |
Liver cancer [ICD-11: 2C12] |
P52732 |
KIF11_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07820 |
MCL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07820 |
MCL1_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
Q07820 |
MCL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Melanoma [ICD-11: 2C30] |
Q07820 |
MCL1_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
Q07820 |
MCL1_HUMAN |
Trematode disease [ICD-11: 1F8Y] |
Q07820 |
MCL1_HUMAN |
Asthma [ICD-11: CA23] |
Q07820 |
MCL1_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
Q07820 |
MCL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07820 |
MCL1_HUMAN |
Malignant intestine neoplasm [ICD-11: 2C0Z] |
Q07820 |
MCL1_HUMAN |
Mastocytosis [ICD-11: 2A21] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07820 |
MCL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07820 |
MCL1_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
Q07820 |
MCL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Melanoma [ICD-11: 2C30] |
Q07820 |
MCL1_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
Q07820 |
MCL1_HUMAN |
Trematode disease [ICD-11: 1F8Y] |
Q07820 |
MCL1_HUMAN |
Asthma [ICD-11: CA23] |
Q07820 |
MCL1_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
Q07820 |
MCL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07820 |
MCL1_HUMAN |
Malignant intestine neoplasm [ICD-11: 2C0Z] |
Q07820 |
MCL1_HUMAN |
Mastocytosis [ICD-11: 2A21] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07820 |
MCL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07820 |
MCL1_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
Q07820 |
MCL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Melanoma [ICD-11: 2C30] |
Q07820 |
MCL1_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
Q07820 |
MCL1_HUMAN |
Trematode disease [ICD-11: 1F8Y] |
Q07820 |
MCL1_HUMAN |
Asthma [ICD-11: CA23] |
Q07820 |
MCL1_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
Q07820 |
MCL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07820 |
MCL1_HUMAN |
Malignant intestine neoplasm [ICD-11: 2C0Z] |
Q07820 |
MCL1_HUMAN |
Mastocytosis [ICD-11: 2A21] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07820 |
MCL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07820 |
MCL1_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
Q07820 |
MCL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Melanoma [ICD-11: 2C30] |
Q07820 |
MCL1_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
Q07820 |
MCL1_HUMAN |
Trematode disease [ICD-11: 1F8Y] |
Q07820 |
MCL1_HUMAN |
Asthma [ICD-11: CA23] |
Q07820 |
MCL1_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
Q07820 |
MCL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07820 |
MCL1_HUMAN |
Malignant intestine neoplasm [ICD-11: 2C0Z] |
Q07820 |
MCL1_HUMAN |
Mastocytosis [ICD-11: 2A21] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07820 |
MCL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07820 |
MCL1_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
Q07820 |
MCL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Melanoma [ICD-11: 2C30] |
Q07820 |
MCL1_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
Q07820 |
MCL1_HUMAN |
Trematode disease [ICD-11: 1F8Y] |
Q07820 |
MCL1_HUMAN |
Asthma [ICD-11: CA23] |
Q07820 |
MCL1_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
Q07820 |
MCL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07820 |
MCL1_HUMAN |
Malignant intestine neoplasm [ICD-11: 2C0Z] |
Q07820 |
MCL1_HUMAN |
Mastocytosis [ICD-11: 2A21] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07820 |
MCL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07820 |
MCL1_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
Q07820 |
MCL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Melanoma [ICD-11: 2C30] |
Q07820 |
MCL1_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
Q07820 |
MCL1_HUMAN |
Trematode disease [ICD-11: 1F8Y] |
Q07820 |
MCL1_HUMAN |
Asthma [ICD-11: CA23] |
Q07820 |
MCL1_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
Q07820 |
MCL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07820 |
MCL1_HUMAN |
Malignant intestine neoplasm [ICD-11: 2C0Z] |
Q07820 |
MCL1_HUMAN |
Mastocytosis [ICD-11: 2A21] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07820 |
MCL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07820 |
MCL1_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
Q07820 |
MCL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Melanoma [ICD-11: 2C30] |
Q07820 |
MCL1_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
Q07820 |
MCL1_HUMAN |
Trematode disease [ICD-11: 1F8Y] |
Q07820 |
MCL1_HUMAN |
Asthma [ICD-11: CA23] |
Q07820 |
MCL1_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
Q07820 |
MCL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07820 |
MCL1_HUMAN |
Malignant intestine neoplasm [ICD-11: 2C0Z] |
Q07820 |
MCL1_HUMAN |
Mastocytosis [ICD-11: 2A21] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07820 |
MCL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07820 |
MCL1_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
Q07820 |
MCL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Melanoma [ICD-11: 2C30] |
Q07820 |
MCL1_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
Q07820 |
MCL1_HUMAN |
Trematode disease [ICD-11: 1F8Y] |
Q07820 |
MCL1_HUMAN |
Asthma [ICD-11: CA23] |
Q07820 |
MCL1_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
Q07820 |
MCL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07820 |
MCL1_HUMAN |
Malignant intestine neoplasm [ICD-11: 2C0Z] |
Q07820 |
MCL1_HUMAN |
Mastocytosis [ICD-11: 2A21] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07820 |
MCL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07820 |
MCL1_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
Q07820 |
MCL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Melanoma [ICD-11: 2C30] |
Q07820 |
MCL1_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
Q07820 |
MCL1_HUMAN |
Trematode disease [ICD-11: 1F8Y] |
Q07820 |
MCL1_HUMAN |
Asthma [ICD-11: CA23] |
Q07820 |
MCL1_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
Q07820 |
MCL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07820 |
MCL1_HUMAN |
Malignant intestine neoplasm [ICD-11: 2C0Z] |
Q07820 |
MCL1_HUMAN |
Mastocytosis [ICD-11: 2A21] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07820 |
MCL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07820 |
MCL1_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
Q07820 |
MCL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Melanoma [ICD-11: 2C30] |
Q07820 |
MCL1_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
Q07820 |
MCL1_HUMAN |
Trematode disease [ICD-11: 1F8Y] |
Q07820 |
MCL1_HUMAN |
Asthma [ICD-11: CA23] |
Q07820 |
MCL1_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
Q07820 |
MCL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07820 |
MCL1_HUMAN |
Malignant intestine neoplasm [ICD-11: 2C0Z] |
Q07820 |
MCL1_HUMAN |
Mastocytosis [ICD-11: 2A21] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07820 |
MCL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07820 |
MCL1_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
Q07820 |
MCL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Melanoma [ICD-11: 2C30] |
Q07820 |
MCL1_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
Q07820 |
MCL1_HUMAN |
Trematode disease [ICD-11: 1F8Y] |
Q07820 |
MCL1_HUMAN |
Asthma [ICD-11: CA23] |
Q07820 |
MCL1_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
Q07820 |
MCL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07820 |
MCL1_HUMAN |
Malignant intestine neoplasm [ICD-11: 2C0Z] |
Q07820 |
MCL1_HUMAN |
Mastocytosis [ICD-11: 2A21] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07820 |
MCL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07820 |
MCL1_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
Q07820 |
MCL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Melanoma [ICD-11: 2C30] |
Q07820 |
MCL1_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
Q07820 |
MCL1_HUMAN |
Trematode disease [ICD-11: 1F8Y] |
Q07820 |
MCL1_HUMAN |
Asthma [ICD-11: CA23] |
Q07820 |
MCL1_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
Q07820 |
MCL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07820 |
MCL1_HUMAN |
Malignant intestine neoplasm [ICD-11: 2C0Z] |
Q07820 |
MCL1_HUMAN |
Mastocytosis [ICD-11: 2A21] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07820 |
MCL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07820 |
MCL1_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
Q07820 |
MCL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Melanoma [ICD-11: 2C30] |
Q07820 |
MCL1_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
Q07820 |
MCL1_HUMAN |
Trematode disease [ICD-11: 1F8Y] |
Q07820 |
MCL1_HUMAN |
Asthma [ICD-11: CA23] |
Q07820 |
MCL1_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
Q07820 |
MCL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07820 |
MCL1_HUMAN |
Malignant intestine neoplasm [ICD-11: 2C0Z] |
Q07820 |
MCL1_HUMAN |
Mastocytosis [ICD-11: 2A21] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07820 |
MCL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07820 |
MCL1_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
Q07820 |
MCL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Melanoma [ICD-11: 2C30] |
Q07820 |
MCL1_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
Q07820 |
MCL1_HUMAN |
Trematode disease [ICD-11: 1F8Y] |
Q07820 |
MCL1_HUMAN |
Asthma [ICD-11: CA23] |
Q07820 |
MCL1_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
Q07820 |
MCL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07820 |
MCL1_HUMAN |
Malignant intestine neoplasm [ICD-11: 2C0Z] |
Q07820 |
MCL1_HUMAN |
Mastocytosis [ICD-11: 2A21] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07820 |
MCL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07820 |
MCL1_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
Q07820 |
MCL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Melanoma [ICD-11: 2C30] |
Q07820 |
MCL1_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
Q07820 |
MCL1_HUMAN |
Trematode disease [ICD-11: 1F8Y] |
Q07820 |
MCL1_HUMAN |
Asthma [ICD-11: CA23] |
Q07820 |
MCL1_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
Q07820 |
MCL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07820 |
MCL1_HUMAN |
Malignant intestine neoplasm [ICD-11: 2C0Z] |
Q07820 |
MCL1_HUMAN |
Mastocytosis [ICD-11: 2A21] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
P14618 |
KPYM_HUMAN |
Pain [ICD-11: MG30-MG3Z] |
P14618 |
KPYM_HUMAN |
Renal cell carcinoma [ICD-11: 2C90] |
P14618 |
KPYM_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P00338 |
LDHA_HUMAN |
Inborn carbohydrate metabolism error [ICD-11: 5C51] |
P07947 |
YES_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P10415 |
BCL2_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
P10415 |
BCL2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
P10415 |
BCL2_HUMAN |
Ovarian cancer [ICD-11: 2C73] |
P10415 |
BCL2_HUMAN |
Pancreatic cancer [ICD-11: 2C10] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Stomach cancer [ICD-11: 2B72] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
P10415 |
BCL2_HUMAN |
Ovarian dysfunction [ICD-11: 5A80] |
P10415 |
BCL2_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Chronic myelomonocytic leukaemia [ICD-11: 2A40] |
P10415 |
BCL2_HUMAN |
Follicular lymphoma [ICD-11: 2A80] |
P10415 |
BCL2_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
P10415 |
BCL2_HUMAN |
Myelodysplastic syndrome [ICD-11: 2A37] |
P10415 |
BCL2_HUMAN |
Psoriasis [ICD-11: EA90] |
P10415 |
BCL2_HUMAN |
Diffuse large B-cell lymphoma [ICD-11: 2A81] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Leukaemia [ICD-11: 2A60-2B33] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Colorectal cancer [ICD-11: 2B91] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Lymphoma [ICD-11: 2A80-2A86] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P10415 |
BCL2_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
P10415 |
BCL2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
P10415 |
BCL2_HUMAN |
Ovarian cancer [ICD-11: 2C73] |
P10415 |
BCL2_HUMAN |
Pancreatic cancer [ICD-11: 2C10] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Stomach cancer [ICD-11: 2B72] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
P10415 |
BCL2_HUMAN |
Ovarian dysfunction [ICD-11: 5A80] |
P10415 |
BCL2_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Chronic myelomonocytic leukaemia [ICD-11: 2A40] |
P10415 |
BCL2_HUMAN |
Follicular lymphoma [ICD-11: 2A80] |
P10415 |
BCL2_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
P10415 |
BCL2_HUMAN |
Myelodysplastic syndrome [ICD-11: 2A37] |
P10415 |
BCL2_HUMAN |
Psoriasis [ICD-11: EA90] |
P10415 |
BCL2_HUMAN |
Diffuse large B-cell lymphoma [ICD-11: 2A81] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Leukaemia [ICD-11: 2A60-2B33] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Colorectal cancer [ICD-11: 2B91] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Lymphoma [ICD-11: 2A80-2A86] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P10415 |
BCL2_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
P10415 |
BCL2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
P10415 |
BCL2_HUMAN |
Ovarian cancer [ICD-11: 2C73] |
P10415 |
BCL2_HUMAN |
Pancreatic cancer [ICD-11: 2C10] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Stomach cancer [ICD-11: 2B72] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
P10415 |
BCL2_HUMAN |
Ovarian dysfunction [ICD-11: 5A80] |
P10415 |
BCL2_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Chronic myelomonocytic leukaemia [ICD-11: 2A40] |
P10415 |
BCL2_HUMAN |
Follicular lymphoma [ICD-11: 2A80] |
P10415 |
BCL2_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
P10415 |
BCL2_HUMAN |
Myelodysplastic syndrome [ICD-11: 2A37] |
P10415 |
BCL2_HUMAN |
Psoriasis [ICD-11: EA90] |
P10415 |
BCL2_HUMAN |
Diffuse large B-cell lymphoma [ICD-11: 2A81] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Leukaemia [ICD-11: 2A60-2B33] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Colorectal cancer [ICD-11: 2B91] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Lymphoma [ICD-11: 2A80-2A86] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P10415 |
BCL2_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
P10415 |
BCL2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
P10415 |
BCL2_HUMAN |
Ovarian cancer [ICD-11: 2C73] |
P10415 |
BCL2_HUMAN |
Pancreatic cancer [ICD-11: 2C10] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Stomach cancer [ICD-11: 2B72] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
P10415 |
BCL2_HUMAN |
Ovarian dysfunction [ICD-11: 5A80] |
P10415 |
BCL2_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Chronic myelomonocytic leukaemia [ICD-11: 2A40] |
P10415 |
BCL2_HUMAN |
Follicular lymphoma [ICD-11: 2A80] |
P10415 |
BCL2_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
P10415 |
BCL2_HUMAN |
Myelodysplastic syndrome [ICD-11: 2A37] |
P10415 |
BCL2_HUMAN |
Psoriasis [ICD-11: EA90] |
P10415 |
BCL2_HUMAN |
Diffuse large B-cell lymphoma [ICD-11: 2A81] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Leukaemia [ICD-11: 2A60-2B33] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Colorectal cancer [ICD-11: 2B91] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Lymphoma [ICD-11: 2A80-2A86] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P10415 |
BCL2_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
P10415 |
BCL2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
P10415 |
BCL2_HUMAN |
Ovarian cancer [ICD-11: 2C73] |
P10415 |
BCL2_HUMAN |
Pancreatic cancer [ICD-11: 2C10] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Stomach cancer [ICD-11: 2B72] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
P10415 |
BCL2_HUMAN |
Ovarian dysfunction [ICD-11: 5A80] |
P10415 |
BCL2_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Chronic myelomonocytic leukaemia [ICD-11: 2A40] |
P10415 |
BCL2_HUMAN |
Follicular lymphoma [ICD-11: 2A80] |
P10415 |
BCL2_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
P10415 |
BCL2_HUMAN |
Myelodysplastic syndrome [ICD-11: 2A37] |
P10415 |
BCL2_HUMAN |
Psoriasis [ICD-11: EA90] |
P10415 |
BCL2_HUMAN |
Diffuse large B-cell lymphoma [ICD-11: 2A81] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Leukaemia [ICD-11: 2A60-2B33] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Colorectal cancer [ICD-11: 2B91] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Lymphoma [ICD-11: 2A80-2A86] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P10415 |
BCL2_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
P10415 |
BCL2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
P10415 |
BCL2_HUMAN |
Ovarian cancer [ICD-11: 2C73] |
P10415 |
BCL2_HUMAN |
Pancreatic cancer [ICD-11: 2C10] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Stomach cancer [ICD-11: 2B72] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
P10415 |
BCL2_HUMAN |
Ovarian dysfunction [ICD-11: 5A80] |
P10415 |
BCL2_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Chronic myelomonocytic leukaemia [ICD-11: 2A40] |
P10415 |
BCL2_HUMAN |
Follicular lymphoma [ICD-11: 2A80] |
P10415 |
BCL2_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
P10415 |
BCL2_HUMAN |
Myelodysplastic syndrome [ICD-11: 2A37] |
P10415 |
BCL2_HUMAN |
Psoriasis [ICD-11: EA90] |
P10415 |
BCL2_HUMAN |
Diffuse large B-cell lymphoma [ICD-11: 2A81] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Leukaemia [ICD-11: 2A60-2B33] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Colorectal cancer [ICD-11: 2B91] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Lymphoma [ICD-11: 2A80-2A86] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P10415 |
BCL2_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
P10415 |
BCL2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
P10415 |
BCL2_HUMAN |
Ovarian cancer [ICD-11: 2C73] |
P10415 |
BCL2_HUMAN |
Pancreatic cancer [ICD-11: 2C10] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Stomach cancer [ICD-11: 2B72] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
P10415 |
BCL2_HUMAN |
Ovarian dysfunction [ICD-11: 5A80] |
P10415 |
BCL2_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Chronic myelomonocytic leukaemia [ICD-11: 2A40] |
P10415 |
BCL2_HUMAN |
Follicular lymphoma [ICD-11: 2A80] |
P10415 |
BCL2_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
P10415 |
BCL2_HUMAN |
Myelodysplastic syndrome [ICD-11: 2A37] |
P10415 |
BCL2_HUMAN |
Psoriasis [ICD-11: EA90] |
P10415 |
BCL2_HUMAN |
Diffuse large B-cell lymphoma [ICD-11: 2A81] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Leukaemia [ICD-11: 2A60-2B33] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Colorectal cancer [ICD-11: 2B91] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Lymphoma [ICD-11: 2A80-2A86] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P10415 |
BCL2_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
P10415 |
BCL2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
P10415 |
BCL2_HUMAN |
Ovarian cancer [ICD-11: 2C73] |
P10415 |
BCL2_HUMAN |
Pancreatic cancer [ICD-11: 2C10] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Stomach cancer [ICD-11: 2B72] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
P10415 |
BCL2_HUMAN |
Ovarian dysfunction [ICD-11: 5A80] |
P10415 |
BCL2_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Chronic myelomonocytic leukaemia [ICD-11: 2A40] |
P10415 |
BCL2_HUMAN |
Follicular lymphoma [ICD-11: 2A80] |
P10415 |
BCL2_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
P10415 |
BCL2_HUMAN |
Myelodysplastic syndrome [ICD-11: 2A37] |
P10415 |
BCL2_HUMAN |
Psoriasis [ICD-11: EA90] |
P10415 |
BCL2_HUMAN |
Diffuse large B-cell lymphoma [ICD-11: 2A81] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Leukaemia [ICD-11: 2A60-2B33] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Colorectal cancer [ICD-11: 2B91] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Lymphoma [ICD-11: 2A80-2A86] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P10415 |
BCL2_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
P10415 |
BCL2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
P10415 |
BCL2_HUMAN |
Ovarian cancer [ICD-11: 2C73] |
P10415 |
BCL2_HUMAN |
Pancreatic cancer [ICD-11: 2C10] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Stomach cancer [ICD-11: 2B72] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
P10415 |
BCL2_HUMAN |
Ovarian dysfunction [ICD-11: 5A80] |
P10415 |
BCL2_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Chronic myelomonocytic leukaemia [ICD-11: 2A40] |
P10415 |
BCL2_HUMAN |
Follicular lymphoma [ICD-11: 2A80] |
P10415 |
BCL2_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
P10415 |
BCL2_HUMAN |
Myelodysplastic syndrome [ICD-11: 2A37] |
P10415 |
BCL2_HUMAN |
Psoriasis [ICD-11: EA90] |
P10415 |
BCL2_HUMAN |
Diffuse large B-cell lymphoma [ICD-11: 2A81] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Leukaemia [ICD-11: 2A60-2B33] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Colorectal cancer [ICD-11: 2B91] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Lymphoma [ICD-11: 2A80-2A86] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P10415 |
BCL2_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
P10415 |
BCL2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
P10415 |
BCL2_HUMAN |
Ovarian cancer [ICD-11: 2C73] |
P10415 |
BCL2_HUMAN |
Pancreatic cancer [ICD-11: 2C10] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Stomach cancer [ICD-11: 2B72] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
P10415 |
BCL2_HUMAN |
Ovarian dysfunction [ICD-11: 5A80] |
P10415 |
BCL2_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Chronic myelomonocytic leukaemia [ICD-11: 2A40] |
P10415 |
BCL2_HUMAN |
Follicular lymphoma [ICD-11: 2A80] |
P10415 |
BCL2_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
P10415 |
BCL2_HUMAN |
Myelodysplastic syndrome [ICD-11: 2A37] |
P10415 |
BCL2_HUMAN |
Psoriasis [ICD-11: EA90] |
P10415 |
BCL2_HUMAN |
Diffuse large B-cell lymphoma [ICD-11: 2A81] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Leukaemia [ICD-11: 2A60-2B33] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Colorectal cancer [ICD-11: 2B91] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Lymphoma [ICD-11: 2A80-2A86] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P10415 |
BCL2_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
P10415 |
BCL2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
P10415 |
BCL2_HUMAN |
Ovarian cancer [ICD-11: 2C73] |
P10415 |
BCL2_HUMAN |
Pancreatic cancer [ICD-11: 2C10] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Stomach cancer [ICD-11: 2B72] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
P10415 |
BCL2_HUMAN |
Ovarian dysfunction [ICD-11: 5A80] |
P10415 |
BCL2_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Chronic myelomonocytic leukaemia [ICD-11: 2A40] |
P10415 |
BCL2_HUMAN |
Follicular lymphoma [ICD-11: 2A80] |
P10415 |
BCL2_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
P10415 |
BCL2_HUMAN |
Myelodysplastic syndrome [ICD-11: 2A37] |
P10415 |
BCL2_HUMAN |
Psoriasis [ICD-11: EA90] |
P10415 |
BCL2_HUMAN |
Diffuse large B-cell lymphoma [ICD-11: 2A81] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Leukaemia [ICD-11: 2A60-2B33] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Colorectal cancer [ICD-11: 2B91] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Lymphoma [ICD-11: 2A80-2A86] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P10415 |
BCL2_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
P10415 |
BCL2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
P10415 |
BCL2_HUMAN |
Ovarian cancer [ICD-11: 2C73] |
P10415 |
BCL2_HUMAN |
Pancreatic cancer [ICD-11: 2C10] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Stomach cancer [ICD-11: 2B72] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
P10415 |
BCL2_HUMAN |
Ovarian dysfunction [ICD-11: 5A80] |
P10415 |
BCL2_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Chronic myelomonocytic leukaemia [ICD-11: 2A40] |
P10415 |
BCL2_HUMAN |
Follicular lymphoma [ICD-11: 2A80] |
P10415 |
BCL2_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
P10415 |
BCL2_HUMAN |
Myelodysplastic syndrome [ICD-11: 2A37] |
P10415 |
BCL2_HUMAN |
Psoriasis [ICD-11: EA90] |
P10415 |
BCL2_HUMAN |
Diffuse large B-cell lymphoma [ICD-11: 2A81] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Leukaemia [ICD-11: 2A60-2B33] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Colorectal cancer [ICD-11: 2B91] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Lymphoma [ICD-11: 2A80-2A86] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P10415 |
BCL2_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
P10415 |
BCL2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
P10415 |
BCL2_HUMAN |
Ovarian cancer [ICD-11: 2C73] |
P10415 |
BCL2_HUMAN |
Pancreatic cancer [ICD-11: 2C10] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Stomach cancer [ICD-11: 2B72] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
P10415 |
BCL2_HUMAN |
Ovarian dysfunction [ICD-11: 5A80] |
P10415 |
BCL2_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Chronic myelomonocytic leukaemia [ICD-11: 2A40] |
P10415 |
BCL2_HUMAN |
Follicular lymphoma [ICD-11: 2A80] |
P10415 |
BCL2_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
P10415 |
BCL2_HUMAN |
Myelodysplastic syndrome [ICD-11: 2A37] |
P10415 |
BCL2_HUMAN |
Psoriasis [ICD-11: EA90] |
P10415 |
BCL2_HUMAN |
Diffuse large B-cell lymphoma [ICD-11: 2A81] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Leukaemia [ICD-11: 2A60-2B33] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Colorectal cancer [ICD-11: 2B91] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Lymphoma [ICD-11: 2A80-2A86] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P10415 |
BCL2_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
P10415 |
BCL2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
P10415 |
BCL2_HUMAN |
Ovarian cancer [ICD-11: 2C73] |
P10415 |
BCL2_HUMAN |
Pancreatic cancer [ICD-11: 2C10] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Stomach cancer [ICD-11: 2B72] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
P10415 |
BCL2_HUMAN |
Ovarian dysfunction [ICD-11: 5A80] |
P10415 |
BCL2_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Chronic myelomonocytic leukaemia [ICD-11: 2A40] |
P10415 |
BCL2_HUMAN |
Follicular lymphoma [ICD-11: 2A80] |
P10415 |
BCL2_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
P10415 |
BCL2_HUMAN |
Myelodysplastic syndrome [ICD-11: 2A37] |
P10415 |
BCL2_HUMAN |
Psoriasis [ICD-11: EA90] |
P10415 |
BCL2_HUMAN |
Diffuse large B-cell lymphoma [ICD-11: 2A81] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Leukaemia [ICD-11: 2A60-2B33] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Colorectal cancer [ICD-11: 2B91] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Lymphoma [ICD-11: 2A80-2A86] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P10415 |
BCL2_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
P10415 |
BCL2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
P10415 |
BCL2_HUMAN |
Ovarian cancer [ICD-11: 2C73] |
P10415 |
BCL2_HUMAN |
Pancreatic cancer [ICD-11: 2C10] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Stomach cancer [ICD-11: 2B72] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P10415 |
BCL2_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
P10415 |
BCL2_HUMAN |
Ovarian dysfunction [ICD-11: 5A80] |
P10415 |
BCL2_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Chronic myelomonocytic leukaemia [ICD-11: 2A40] |
P10415 |
BCL2_HUMAN |
Follicular lymphoma [ICD-11: 2A80] |
P10415 |
BCL2_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
P10415 |
BCL2_HUMAN |
Myelodysplastic syndrome [ICD-11: 2A37] |
P10415 |
BCL2_HUMAN |
Psoriasis [ICD-11: EA90] |
P10415 |
BCL2_HUMAN |
Diffuse large B-cell lymphoma [ICD-11: 2A81] |
P10415 |
BCL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10415 |
BCL2_HUMAN |
Leukaemia [ICD-11: 2A60-2B33] |
P10415 |
BCL2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P10415 |
BCL2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10415 |
BCL2_HUMAN |
Colorectal cancer [ICD-11: 2B91] |
P10415 |
BCL2_HUMAN |
Lung cancer [ICD-11: 2C25] |
P10415 |
BCL2_HUMAN |
Lymphoma [ICD-11: 2A80-2A86] |
P10415 |
BCL2_HUMAN |
Melanoma [ICD-11: 2C30] |
P10415 |
BCL2_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P11166 |
GTR1_HUMAN |
Skin disease [ICD-11: EA00-EM0Z] |
Q92843 |
B2CL2_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
Q92843 |
B2CL2_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q92843 |
B2CL2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |